M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Vorinostat Plus Radiation Therapy in Pancreatic Cancer

Phase 1

Terminated

Conditions: Pancreatic Cancer

Interventions: Radiation: Chemoradiation (Radiation Therapy)
Drug: Vorinostat

First Posted Date: 2009-01-29

Last Posted Date: 2012-02-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 3

Registration Number: NCT00831493

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

TKI258 in Castrate Resistant Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: TK1258

First Posted Date: 2009-01-29

Last Posted Date: 2019-09-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 46

Registration Number: NCT00831792

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Attitudes About Childbearing And Fertility With Inherited Breast And Ovarian Cancer Syndromes (HBOC)

Completed

Conditions: Breast Cancer
Ovarian Cancer

Interventions: Behavioral: Questionnaire

First Posted Date: 2009-01-27

Last Posted Date: 2016-08-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 156

Registration Number: NCT00829959

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

M. D. Anderson Symptom Inventory - Heart Failure (MDASI-HF) Symptom Management Program

Completed

Conditions: Heart Failure
Cancer

Interventions: Behavioral: MDASI-HF Questionnaire

First Posted Date: 2009-01-23

Last Posted Date: 2012-07-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 26

Registration Number: NCT00827801

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

PET-CT in the Management of Patients With Stage III or IV Metastatic Melanoma

Completed

Conditions: Melanoma

Interventions: Procedure: PET-CT Scan

First Posted Date: 2009-01-23

Last Posted Date: 2012-03-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 38

Registration Number: NCT00828126

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)

Phase 1

Completed

Conditions: Non-Small Cell Lung Cancer
Lung Cancer

Interventions: Drug: Dasatinib
Drug: Erlotinib

First Posted Date: 2009-01-22

Last Posted Date: 2016-06-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 53

Registration Number: NCT00826449

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Formative Study of Tailored Survivor Health Promotion

Completed

Conditions: Colorectal Cancer

Interventions: Behavioral: One-time Questionnaire + Recorded Qualitative Interview

First Posted Date: 2009-01-19

Last Posted Date: 2015-03-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 15

Registration Number: NCT00825240

Locations: 🇺🇸
The Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, Texas, United States
🇺🇸
Kelsey Research Foundation, Houston, Texas, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Evaluation Ultrasound Elasticity/Tissue Strain-Hardening Imaging for Prostate Cancer Patients Undergoing Radical Prostatectomy

Not Applicable

Terminated

Conditions: Prostate Cancer

Interventions: Procedure: Tissue Elastography Imaging

First Posted Date: 2009-01-19

Last Posted Date: 2015-01-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 13

Registration Number: NCT00824902

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients

Phase 3

Completed

Conditions: Hematological Malignancies

Interventions: Drug: Ibandronate
Drug: Vitamin Supplements

First Posted Date: 2009-01-19

Last Posted Date: 2018-09-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 78

Registration Number: NCT00824993

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel

Phase 2

Withdrawn

Conditions: Epiphora

Interventions: Drug: Cyclosporine Eye Drops (Restasis)
Drug: Lubricant Eye Drops (Refresh Endura™)
Drug: Fluorometholone Eye Drops (FML Forte®)

First Posted Date: 2009-01-19

Last Posted Date: 2012-08-02

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT00824811

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy